Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias

Stopped No responders in parent protocol 000758; this follow-on protocol not activated and PI leaving NIH

Conditions

• Immune Mediated Anemia
• Immune Mediated Thrombocytopenia
• Chronic GVHD

Interventions

• DRUG: fostamatinib

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)